Loading clinical trials...

ACTIVE_NOT_RECRUITING

REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

Registry of the Natural History of Recurrent Pericarditis in Pediatric and Adult Patients

NCT04687358•Kiniksa Pharmaceuticals International, plc

Summary

The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.

Eligibility

Age

7 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•ACTIVE RP PATIENTS
•Physician-confirmed (or confirmation in medical records) diagnosis of RP defined as an initial, acute, episode and at least one pericarditis recurrence after the initial acute episode
•Experienced at least one pericarditis episode in the 3 years prior to inclusion
•Under the care of a physician for the treatment and management of RP
•Currently prescribed medication for RP
•Physician-confirmed (or confirmation in medical records) diagnosis of RP defined as an initial, acute, episode and at least one pericarditis recurrence after the initial, acute episode
•Patient had a last episode occurring at least 3 years and up to 5 years before registry inclusion
•Resolution of RP symptoms confirmed with no further RP treatment for 3 years prior to registry enrollment

Exclusion Criteria

•Diagnosis of pericarditis secondary to tuberculosis (TB), cancer if not in full remission, post thoracic blunt trauma (e.g., motor-vehicle accidents), myocarditis, systemic autoimmune diseases, except SJIA and adult Still's disease, HIV
•Appears to have an impairment (e.g., cognitive, hearing, visual) or insufficient English or Spanish proficiency that could interfere with ability to complete patient-completed assessments
•Currently enrolled in a therapeutic investigational drug or device study
•INACTIVE RP PATIENTS
•Experienced a pericarditis episode within 3 years from enrolling in the registry
•Currently receiving RP treatment prescribed by a treating physician (e.g., CS, colchicine)
•Diagnosis of pericarditis secondary to tuberculosis (TB), cancer if not in full remission, post thoracic blunt trauma (e.g., motor-vehicle accidents), myocarditis, systemic autoimmune diseases except SJIA and adult Still's disease, HIV
•Enrolled in a therapeutic investigational clinical trial during the observation period

Locations (29)

Alaska Heart & Vascular Institute

Anchorage, Alaska, United States

Pima Heart and Vascular

Tucson, Arizona, United States

University of California San Diego Medical Center

La Jolla, California, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

Scripps Health

San Diego, California, United States

Northwestern University

Chicago, Illinois, United States

Midwest Cardiovascular Research Foundation

Davenport, Iowa, United States

Johns Hopkins University

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Key Dates

Start Date

March 16, 2021

Primary Completion Date

March 1, 2029

Completion Date

March 1, 2029

Last Updated

February 17, 2026

Enrollment

500

ESTIMATED participants

Conditions

Recurrent Pericarditis

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

NCT06836232

Recurrent Pericarditis

View study

COMPLETEDPHASE3

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

NCT03737110

Recurrent Pericarditis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions